Primed to Kill: CTV-1 Stimulated Haploidentical Natural Killer Cells for Consolidation of AML

In this issue of Biology of Blood and Marrow Transplantation, Fehniger et al report results of a Phase 1 dose escalation trial of AML patients in first complete remission (CR1) who received a single infusion of haploidentical CTV-1 primed NK cells (henceforth referred to as CNDO-109), preceded by lymphodepleting chemotherapy.1 Twelve elderly AML patients received a single dose of Cyclophosphamide and four doses of Fludarabine followed by 3  × 105/kg, 1 × 106/kg, or 3 × 106/kg CNDO-109 cells. All patients were ineligible for HSCT, but at high-risk of relapse based on predetermined characteristics including cytogenetic features, age and therapy-related AML.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research